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Abstract
 
Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a key cytokine in my-
elopoiesis and aberrant expression is associated with chronic inflammatory disease and my-
eloid leukemias. This aberrant expression is often associated with constitutive nuclear factor
 
(NF)-
 
 
 
B activation. To investigate the relationship between NF-
 
 
 
B and GM-CSF tran-
scription in a chromatin context, we analyzed the chromatin structure of the GM-CSF gene
in T cells and the role of NF-
 
 
 
B proteins in chromatin remodeling. We show here that
chromatin remodeling occurs across a region of the GM-CSF gene between 
 
 
 
174 and 
 
 
 
24
upon T cell activation, suggesting that remodeling is limited to a single nucleosome encom-
passing the proximal promoter. Nuclear NF-
 
 
 
B levels appear to play a critical role in this
process. In addition, using an immobilized template assay we found that the ATPase compo-
nent of the SWI/SNF chromatin remodeling complex, brg1, is recruited to the GM-CSF
proximal promoter in an NF-
 
 
 
B–dependent manner in vitro. These results suggest that
chromatin remodeling across the GM-CSF promoter in T cells is a result of recruitment of
SWI/SNF type remodeling complexes by NF-
 
 
 
B proteins binding to the CD28 response
region of the promoter.
Key words: transcription • chromatin remodeling • Brg1 • cytokine • RelA
 
Introduction
 
GM-CSF is a key cytokine involved in the production and
function of myeloid cells (1–3). GM-CSF is induced in a
variety of cell types, including T cells, macrophages, endo-
thelial cells, and fibroblasts in response to immune and in-
flammatory signals (1–3). In T cells, GM-CSF expression is
rapidly and transiently induced after T cell receptor stimu-
lation and costimulation through CD28:B7 interactions (4).
Dysregulated expression of GM-CSF is most likely a con-
tributing factor in a range of pathological conditions in-
cluding leukemias (5, 6) and chronic inflammatory diseases
such as rheumatoid arthritis (7). These diseases are often
associated with constitutive expression of transcription fac-
tors such as NF-
 
 
 
B (8, 9).
The production of GM-CSF is regulated primarily at
the level of transcription, via proximal promoter and en-
hancer regions (10–12), although posttranscriptional con-
trol also contributes to the final level of mRNA and pro-
tein (13). The GM-CSF proximal promoter (
 
 
 
1 to 
 
 
 
100)
consists of a complex array of well characterized transcrip-
tion factor binding sites (see Fig. 1 A; for a review, see ref-
erence 14). The NF-
 
 
 
B family of transcription factors
plays an important role in the induction of GM-CSF ex-
pression via a region of the proximal promoter known as
the CD28 response region (CD28RR; Fig. 1 A). This re-
gion consists of a variant NF-
 
 
 
B site, known as CK-1 or
CD28RE, a classical NF-
 
 
 
B site and an adjacent Sp1 site
(15) which all serve to integrate signals from the T cell re-
ceptor and the CD28 costimulatory signal (4, 16, 17). The
state of chromatin condensation across specific genes in
the nucleus forms an important level of control in the reg-
ulation of inducible gene transcription (for reviews, see
references 18 and 19). The formation of DNase I hyper-
 
sensitive (DH)
 
*
 
 sites has been observed in the enhancer
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and promoter regions of the GM-CSF gene upon T cell
activation (11, 20), suggesting that changes in chromatin
structure occur across these regions. Furthermore, the
CD28RR has been implicated in these events at the pro-
moter (21). A mutation in the NF-
 
 
 
B/Sp1 region of the
CD28RR blocked induction of the DH site in the hu-
man GM-CSF promoter in a transgenic mouse model re-
sulting in an inactive transgene (21). Interestingly, this
mutation in the CD28RR reduced activation of the hu-
man GM-CSF gene only when it was integrated into
chromosomal DNA (21), indicating that factors which
bind to or are recruited to the CD28RR may play a key
role in the reorganization of chromatin structure across
the GM-CSF promoter.
Currently, there are two general mechanisms by which
chromatin structure is known to be altered to allow gene
transcription to occur (for reviews, see references 19 and
22). First, multi-subunit ATP-dependent remodeling com-
plexes have been identified (for a review, see reference 23),
which use the energy of ATP hydrolysis to disrupt his-
tone–DNA interactions. Second, histone modifying com-
plexes which alter histone NH
 
2
 
-terminal tails are thought
to regulate gene transcription by disrupting chromatin
structure and/or providing a histone code that is targeted
by other proteins (24–26). One model suggests that chro-
matin modifying/remodeling complexes are recruited to
specific promoter regions through interactions with DNA
bound transcription factors which are able to access their
binding sites in a chromatin context (for reviews, see refer-
ences 23 and 25).
In this study, we show that upon T cell activation
changes in chromatin structure occur across a specific re-
gion of the GM-CSF proximal promoter, limited to a re-
gion of less than 200 bp. NF-
 
 
 
B proteins appear to play a
critical role in these chromatin remodeling events, which
precede GM-CSF gene transcription. Using an in vitro re-
cruitment assay, we show that the NF-
 
 
 
B sites of the
CD28RR may play a critical role in recruitment of brg1-
containing complexes to the GM-CSF promoter.
 
Materials and Methods
 
Plasmids.
 
A pGMSelect plasmid, containing a 4.5 kb BamHI-
EcoRI fragment of the human GM-CSF gene was used to mu-
tate the GM-CSF promoter (indicated in Fig. 6 A) using Altered
site II (Promega). pCMV4sI
 
 
 
B
 
 
 
S32/36Aflag was provided by
Dr. D. Ballard, Vanderbilt University School of Medicine, Nash-
ville, TN (27). The mouse GM-CSF constructs, AOGM and
pMGM2.4luc, were provided by Dr. P. Cockerill, University of
Leeds, Leeds, UK (28).
 
Cell Culture and Preparation of Stable Cell Lines.
 
Jurkat T cells
and EL-4 T cells were grown as described previously (15). Cells
were stimulated with 20 ng/ml PMA (Boehringer), 1 
 
 
 
M cal-
cium ionophore (A23187; Sigma-Aldrich), 10 
 
 
 
g/ml murine
CD28 receptor antibody (clone 37NF1; provided by Dr. A.
Strasser) and pretreated with 1 
 
 
 
M MG-115 (Carbobenzoxy-
 
l
 
-
leucyl-
 
l
 
-leucyl-norvalinal; Boehringer) for 1 h before stimulation.
Cells were transfected by electroporation with 10 
 
 
 
g of the plas-
mid of interest and 1 
 
 
 
g of pcDNA3.1 for selection, as described
previously (15). Transfected cells were selected in media contain-
ing 800 
 
 
 
g/ml of G418 then maintained in 400 
 
 
 
g/ml G418.
 
Nuclear Extracts.
 
Nuclear extracts were prepared by the
method of Schreiber et al. (29). Protein concentrations were de-
termined by Bradford Assay (Bio-Rad Laboratories).
 
RNA Isolation and Real-Time PCR Analysis.
 
Total RNA was
isolated from 5 
 
 
 
 10
 
6
 
 cells using Tri Reagent (Sigma-Aldrich).
cDNA was prepared and SYBR Green PCR reactions performed
as described previously (30) with 50 ng cDNA in a total volume
of 25 
 
 
 
l. The GM-CSF primer set 
 
 
 
II (Table I) was used. PCR
reactions conducted in parallel using GAPDH primers (sense: 5
 
 
 
-
CATGGAGAAGGCTGGGGCTC-3
 
 
 
 and antisense: AACG-
GATACATTGGGGGTAG-3
 
 
 
) were used to normalize for dif-
ferences in cDNA synthesis and RNA input.
 
Chromatin Accessibility by Real-Time PCR.
 
Accessibility of
DNA to digestion with restriction enzymes and MNase was ana-
lyzed using chromatin accessibility by real-time PCR (CHART-
PCR) as described previously (30). EL-4 T cell nuclei (5 
 
 
 
 10
 
6
 
nuclei per 100 
 
 
 
l) were treated with 80 units HaeIII or 100 units
HinfI enzyme (Boehringer) at 37
 
 
 
C for 45 min or with 50 units
MNase (Boehringer) for 5 min at 20
 
 
 
C. Genomic DNA (50 ng)
was isolated and analyzed by SYBR Green real-time PCR (30).
The primer sets used are shown in Table I. Accessibility was de-
termined by correlating the Ct values from the amplification plots
to a standard curve generated with genomic DNA, and was ex-
 
Table I.
 
Primer Sequences for SYBR Green Real-Time PCR Analysis
 
Set Sense primer (5
 
 
 
–3
 
 
 
)
 
a
 
Antisense primer (5
 
 
 
–3
 
 
 
)
 
a
 
 
 
II
 
AAGGTCCTGAGGAGGATGTG GAGGTTCAGGGCTTCTTTGA
 
 
 
I
 
GAGTTCTGTGGTCACCATTAATCA CACATCCTCCTCAGGACCTT
 
 
 
I
 
GCCTGACAACCTGGGGGAAG TGATTAATGGTGACCACAGAACTC
 
 
 
II
 
AAAAGGAGAGGCTAGCCAGA TAAGCCCTTCCAAGAACTGG
 
 
 
III
 
CCAGGAAATCCAAATATGCC CAGTCTGACCCAGCCTCTG
 
 
 
IV
 
GAACAGCAGGTGCTATGGAA GGCATATTTGGATTTCCTGG
 
 
 
V
 
TGGAATGAGCCACCAGAGTA GGCTCTTGCTTCCATAGCAC
 
 
 
VI
 
CATTGGGCTGGACCTTATTT TACTCTGGTGGCTCATTCCA
 
 
 
VII
 
TCATTCTCACTGCTCCCAAG ATAAGGTCCAGCCCAATGAC
 
a
 
The primer sequences were designed using the murine GM-CSF gene sequence (GenBank/EMBL/DDBJ accession number X03020).T
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pressed as a percentage of undigested genomic DNA for each
primer set.
 
PCR Amplification from Mononucleosomal DNA.
 
Mononu-
cleosomal DNA was prepared from formaldehyde-fixed EL-4 T
cells as described previously (31). EL-4 T cells (5 
 
 
 
 10
 
5
 
 cells)
were fixed for 10 min with 1% formaldehyde and the reaction
stopped by addition of 0.125 M glycine. Cells were washed and
incubated in 0.5 ml buffer A (10 mM Tris, pH 7.4, 10 mM
NaCl, 3 mM MgCl
 
2
 
, 0.1 mM EDTA. 0.5% NP-40, containing
protease inhibitors) containing 60 ng/ml spermine and 315 ng/
ml spermidine for 5 min at 4
 
 
 
C. Cell nuclei were recovered by
centrifugation at 800 
 
g
 
 for 5 min at 4
 
 
 
C, resusupended in MNase
buffer, incubated with 50 units MNase for 10 min at 37
 
 
 
C, and
then incubated in 0.3 M NaCl at 65
 
 
 
C for 16 h to reverse the
cross-links. Mononucleasome fragments (150–200 bp) were pu-
rified from an agarose gel and resuspended in 30 
 
 
 
l of MilliQ
water. PCR amplification was performed with 4 
 
 
 
l of mononu-
cleosomal DNA, 20 ng of genomic DNA, or 100 pg
pMGM2.4luc plasmid DNA using 0.5 U Taq DNA Polymerase
(Fisher Biotech).
 
Nucleosome Assembly.
 
Chicken long chromatin was prepared
as described previously (32). A fragment of the mouse GM-CSF
promoter (
 
 
 
179 to 
 
 
 
24) was amplified by PCR from the
pAOGM plasmid using a biotinylated sense primer. After diges-
tion at restriction enzyme sites in the primers, the PCR product
was radiolabeled with 
 
32
 
P
 
 
 
-dATP using Klenow DNA polymer-
ase. Nucleosomes were assembled onto the DNA by the salt gra-
dient dialysis method (33). Mock assembled and nucleosome as-
sembled DNA was incubated with 10–40 units of HinfI
restriction enzyme, electrophoresed through 5% polyacrylamide/
1
 
  
 
TBE and visualized using the Fuji PhosphorImager.
 
Immobilized Template Assay.
 
Template assays were performed
by a modification of the method of Ranish et al. (34). A fragment
of the human GM-CSF promoter (
 
 
 
120 to 
 
 
 
45) was amplified
by PCR from the pGMselect wild-type and mutant plasmids us-
ing a biotinylated sense primer. The PCR product was purified
by gel electrophoresis and eluted using the QIAGEN QIAquick
gel extraction kit. The template (150 ng per reaction) was bound
to 15 
 
 
 
l Dynabeads M280 Streptavidin (Dynal) as described pre-
viously (34). The prepared template was blocked for 15 min at
room temperature in 50 
 
 
 
l binding buffer (20 mM HEPES, pH
7.9, 100 mM NaCl, 5 mM MgCl
 
2
 
, 0.5 mM EDTA, 0.01% NP-
40, 10% glycerol) containing 0.1 mg/ml BSA. Alternatively as-
sembled or mock assembled nucleosome reactions were incu-
bated with Dynabeads overnight at 4
 
 
 
C, washed three times in
binding buffer, and blocked similarly.
After blocking, beads were washed three times in binding
buffer and resuspended in 10 
 
 
 
l binding buffer. Nuclear extracts
(250 
 
 
 
g per reaction) were diluted fourfold and supplemented so
that the reaction conditions were equivalent to those in binding
buffer. Reaction mix was supplemented with 4.5 
 
 
 
g poly(dI:dC),
4.5 
 
 
 
g sheared salmon sperm DNA and protease inhibitors, and
incubated on ice for 10 min. The DNA template was added to
the nuclear extracts and incubated for 2 h at 4
 
 
 
C with mixing.
The beads were washed three times with binding buffer contain-
ing 1 mM DTT, 1 mg/ml BSA, and protease inhibitors. Proteins
were eluted from the beads in SDS load buffer, resolved by SDS-
PAGE, transferred to nitrocellulose, and subjected to Western
analysis using anti-RelA (Santa Cruz Biotechnology, Inc.), anti-
Sp1 (Santa Cruz Biotechnology, Inc.), anti-CBP (Santa Cruz
Biotechnology, Inc.), and anti-brg1 (35) antibodies. Proteins
were detected using SuperSignal Chemiluminescent substrate
(Pierce Chemical Co.), visualized using the Fuji luminescent im-
 
age analyzer (Las-1000 plus), and quantified using the Fuji Image
Gauge software.
 
Results
 
Chromatin Is Remodeled Across the Proximal Promoter Region
of the GM-CSF Gene After T Cell Activation.
 
To investi-
gate changes in chromatin structure across the GM-CSF
gene upon T cell activation, accessibility of the gene to mi-
crococcal nuclease (MNase) or restriction enzyme digestion
after T cell activation was measured using a real-time PCR
assay (CHART-PCR; reference 30) and nine primer sets
which amplify regions of 
 
 
 
100 base pairs from 
 
 
 
633 to
 
 
 
164 (Fig. 1 A, primer sets 
 
 
 
VII to  II). PCR amplifica-
tion was monitored by SYBR green incorporation (36).
The amount of PCR product generated from MNase di-
gested samples was plotted as a percentage of that generated
from undigested samples for each primer set.
In nonstimulated cells accessibility of different regions
of the GM-CSF gene to MNase digestion was not uni-
form and ranged from  25 to 60% accessibility across the
region of the gene examined (see Fig. 1 B, open bars; Fig.
1 C, black line). There were two regions which were less
accessible to digestion with MNase, one centered in the
vicinity of the proximal promoter (  100 bp) and an-
other further upstream at about  350 to  400 bp. These
regions of relative inaccessibility to MNase may indicate
the preferred positions of nucleosomes on the uninduced
GM-CSF promoter.
To further investigate nucleosome positioning across the
GM-CSF promoter, mononucleosomal DNA of average
size 150 bp, was prepared by MNase digestion of formalde-
hyde cross-linked EL-4 T cells (Fig. 1 D) and used in PCR
reactions with the primer sets indicated in Fig. 1 A. While
all the primer sets amplified appropriate size products from
genomic DNA or from a plasmid containing the GM-CSF
promoter (Fig. 1 D), only specific primer sets gave strong
PCR products from the mononucleosomal DNA (Fig. 1
E). It should be noted that primer set  I cannot amplify
from the plasmid because the insert does not contain this
part of the GM-CSF gene. Primer set  I gave a strong
PCR product from the mononucleosomal DNA whereas
flanking primer sets  II and  I gave little or no product
(Fig. 1 E). The lower band seen in primer sets  I and  II
most likely represent primer dimers that are also seen in the
control sample lanes. Similarly, primer set  V yielded a
strong PCR product from mononucleosomal DNA whereas
sets  IV and  VI did not (Fig. 1 E). These data support
the possibility that nucleosomes are preferably positioned at
regions centered at  100 and  400.
Upon T cell stimulation the region covered by primer
set  I ( 155 to  40 spanning the CD28RR, see Fig. 1 A)
became significantly more accessible ( 3.4-fold) to MNase
digestion (Fig. 1 B, open bars). The CD28RR is important
for induction of GM-CSF gene expression upon T cell ac-
tivation (37–39). Set  I ( 63 to  43) that spans the tran-
scription start site became slightly more accessible ( 1.4-
fold) to MNase digestion upon T cell activation (Fig. 1 B).T
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This primer set covers AP-1 and NFAT/Ets binding sites,
which are also important for promoter activity (37, 40, 41).
The region downstream of the transcription start site, cov-
ered by primer set  II ( 24 to  164) and the regions up-
stream of the proximal promoter covered by primer sets
 II through to  VII did not show any significant changes
in accessibility after T cell stimulation (Fig. 1 B). There-
fore, changes in MNase accessibility upon T cell stimula-
tion were limited to a 200 bp region assayed with primer
sets  I and  I, which covers the proximal promoter ele-
ments and the transcription start site (Fig. 1 C).
To confirm the changes in accessibility of the GM-CSF
gene upon T cell stimulation, the accessibility of HinfI (F)
and HaeIII (H) restriction enzyme sites across the GM-CSF
gene were also analyzed (see Fig. 1 A). The HinfI sites at
 97 and  548 (as assayed using primer set  I and  VII,
respectively) showed intrinsic accessibility ( 30% at both
sites, see Fig. 2 A), in agreement with the intrinsic accessi-
bility to MNase digestion. Upon T cell stimulation the
HinfI site at  97 became more accessible again supporting
the data generated using MNase (Fig. 2 A). Importantly, this
HinfI site is adjacent to the CK-1 site within the CD28RR
of the GM-CSF promoter. In contrast, the distal HinfI site
at  548 did not become more accessible to restriction en-
zyme digestion upon T cell stimulation (Fig. 2 A).
The accessibility of 2 HaeIII restriction enzyme sites (at
 105 and  127, both amplified by primer set  I) before
and after T cell stimulation was also monitored using
CHART-PCR. Using this primer set, accessibility to
HaeIII digestion upon T cell activation increased (Fig. 2 B)
implying that either one or both of these HaeIII sites be-
came more accessible to digestion upon T cell stimulation.
In contrast, the HaeIII site further upstream at  219, dis-
played no change in accessibility upon T cell stimulation
(Fig. 2 B, primer set  II) as was also seen with HaeIII sites
at  281,  383, and  483 (Fig. 2 C). Similarly, HaeIII
sites downstream of the transcription start site (at  122 and
 141) assayed with primer set  II did not display any
changes in accessibility upon T cell stimulation (Fig. 2 B),
in keeping with data generated with MNase digestion.
These data for both MNase and restriction enzyme accessi-
bility clearly demonstrate that significant changes in chro-
matin structure are limited to a region encompassing the
proximal GM-CSF promoter.
Put together, these data point to the presence of a nu-
cleosome spanning the GM-CSF promoter in resting T
cells, which becomes remodeled upon T cell activation.
Characteristics of Chromatin Remodeling across the GM-CSF
Promoter after T Cell Stimulation. The timing of chromatin
remodeling events across the proximal promoter region of
the GM-CSF gene after T cell stimulation, and the rela-
tionship of these events to transcription from the GM-CSF
gene were investigated. As described earlier, in nonstimu-
lated cells, the region covered by primer set  I displayed a
low level of inherent accessibility to digestion (Fig. 3 A),
which was unchanged at 30 min after stimulation. How-
ever, 1 h after stimulation, accessibility at this site had in-
creased approximately threefold (Fig. 3 A) and this was
maintained for up to 6 h when levels of accessibility started
to decline (Fig. 3 A).
Figure 1. Accessibility of regions of the GM-CSF gene
to MNase digestion. (A) Schematic representation of the
GM-CSF gene showing transcription factor binding sites
and the CD28RR of the promoter. DNA fragments am-
plified by primer sets  VII to  II and HinfI (F) and
HaeIII (H) restriction enzymes sites are indicated. (B) Nu-
clei from nonstimulated (white bars) or 4 h P/I stimulated
(black bars) EL-4 T cells were incubated with MNase. Ge-
nomic DNA was analyzed by real-time PCR using the in-
dicated primer sets. The mean and standard error of three
replicate assays are shown. (C) Percentage accessibility de-
termined in B for nonstimulated (black line) and stimulated
(gray line) nuclei was plotted against position on the
GM-CSF gene corresponding to the midpoint of each
PCR product. Transcription factor binding sites in the
GM-CSF promoter are represented. (D) Agarose gel puri-
fied mononucleosome-size DNA fragments generated by
MNase digestion of formaldehyde cross-linked EL-4 T
cells (lane 2), genomic DNA from formaldehyde cross-
linked cells digested with MNase to generate mononucleo-
some-size fragments (lane 3) and genomic DNA from un-
treated cells were run on a 2% agarose gel. Lane 1 contains
a DNA marker ladder. (E) PCR amplification with primer
sets from A as indicated using mononucleosomal DNA
(lane 1), pMGM2.4luc plasmid DNA (lane 2), genomic
DNA (lane 3), and no DNA as a control (lane 4). The
PCR products are shown for each primer set after agarose
gel electrophoresis. Faster migrating bands are likely to
represent primer dimers.T
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To correlate these remodeling events with transcription,
GM-CSF mRNA levels were analyzed from EL-4 T cells
stimulated in parallel by quantitative real-time PCR using
primer set  II ( 24 to  164), which covers a transcribed
region of the GM-CSF gene (see Fig. 1 A). Little increase
in GM-CSF gene transcription was detected 1 h after stim-
ulation (Fig. 3 B). However, RNA levels dramatically in-
creased after this time with a 70-fold increase seen after 2 h
stimulation and  600-fold after 6 h simulation. This is in
keeping with previous studies, where maximum levels of
transcription were detected after 8–10 h of stimulation us-
ing RNase protection (11). Chromatin remodeling events
across the promoter, therefore, precede significant tran-
scription from the gene and begin to decline before the
time of maximum mRNA accumulation.
We next examined the stimulation conditions required
for chromatin accessibility changes across the GM-CSF
promoter. P/I stimulation lead to increased accessibility for
HinfI digestion across the proximal promoter but treatment
with a CD28 activating antibody together with P/I, did
not increase the level of HinfI accessibility (Fig. 3 C). In
contrast, levels of GM-CSF mRNA were increased by
CD28 activation (Fig. 3 C), implying that the signals gen-
erated by P/I are sufficient to lead to changes in chromatin
accessibility but that CD28 signals increase the levels of
mRNA via a distinct mechanism.
Remodeling of the GM-CSF Promoter Is Dependent on NF-
 B Proteins. As the CD28RR region of the human GM-
CSF promoter has been previously implicated in the for-
mation of an inducible DH site (21), the role of NF- B
proteins in generating MNase or RE accessibility across the
GM-CSF promoter after stimulation was examined. EL-4
T cells were pretreated with the proteasome inhibitor MG-
115 for 1 h before stimulation, preventing degradation of
the I B proteins and subsequent translocation of NF- B
proteins to the nucleus (unpublished data; reference 42).
The MG-115 inhibitor had no effect on the inherent basal
level of accessibility seen in nonstimulated cells (unpub-
lished data). However, in stimulated cells treatment with
MG-115 reduced the increase in accessibility by almost
fourfold (Fig. 4 A). To further assess the effect of inhibiting
NF- B translocation to the nucleus, EL-4 T cells were sta-
bly transfected with a mutant I B  construct which cannot
be phosphorylated and thus prevents NF-kB translocation
Figure 2. Accessibility of regions of the GM-CSF
gene to restriction enzyme digestion. Nuclei from
nonstimulated (white bars) or 4 h P/I stimulated (black
bars) EL-4 T cells were incubated with HinfI (A) or
HaeIII (B) restriction enzyme. Genomic DNA was an-
alyzed by real-time PCR, using the indicated primer
sets. The mean and standard error of three replicate
assays are shown. (C) Changes in accessibility in 4 h
P/I stimulated nuclei compared with nonstimulated
EL-4 T cell nuclei as determined with MNase (gray
line) and restriction enzymes (black line) were plotted
against position across the GM-CSF gene. For restric-
tion enzymes the position of each cutting site was plotted and for MNase the position corresponding to the midpoint of each PCR product was plotted.
Transcription factor binding sites in the GM-CSF promoter are represented.
Figure 3. Characteristics of chromatin remodeling at the GM-CSF
promoter in stimulated EL-4 T cells. (A) Nuclei from nonstimulated EL-4
T cells and cells stimulated with P/I for the indicated time periods, were
incubated with MNase. Genomic DNA was analyzed by real-time PCR
analysis, using primer set  I. (B) Data generated in A was graphed as fold
change in accessibility at each time point compared with nonstimulated
(gray line). GM-CSF mRNA levels were determined by real-time PCR
analysis of cDNA prepared from EL-4 T cells treated as in A, using
primer set  II. Data is graphed as fold change in RNA levels at each time
point compared with nonstimulated (black line). (C) Nuclei from EL-4 T
cells either nonstimulated or stimulated with P/I and P/I/antiCD28 anti-
body for 4 h, were incubated with HinfI. Genomic DNA was analyzed as
in A. GM-CSF mRNA levels in cells treated in parallel, were determined
as in B and are indicated below.T
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to the nucleus (27, 43). Levels of RelA protein were re-
duced by  50% in stimulated EL-4-I B  nuclear extracts
compared with extracts from cells transfected with the
empty vector (Fig. 4 B, compare lanes 4 and 2). Levels of
the transcription factor Sp1 or the ATPase component of
the SWI/SNF chromatin remodeling complex, brg1, were
unaffected in the nuclei of the EL-4-I B  cells (Fig. 4 B).
Primer set  I was used to assay the accessibility of the
HaeIII sites in the proximal promoter region of the GM-
CSF gene in nonstimulated EL-4-I B  cells and cells stim-
ulated with P/I for 2 h. The change in accessibility nor-
mally seen upon stimulation was reduced by 40% in the
EL-4-I B  cell line (Fig. 4 C), in line with the 50% reduc-
tion observed in RelA levels. The level of GM-CSF
mRNA was also reduced by  40% in the I B -transfected
cells (Fig. 4 D) compared with the control CMV-trans-
fected cells (set at 100%) consistent with the reduction in
promoter accessibility.
Therefore, reduction of NF- B protein levels in the nu-
cleus lead to a reduction in chromatin remodeling at the
GM-CSF promoter as well as a reduction in transcription
from the gene. This suggests that NF- B proteins play a
role in chromatin remodeling events at the GM-CSF pro-
moter upon T cell activation.
Brg1 Can Be Recruited to the GM-CSF Promoter In Vi-
tro. From the data above, it is possible that the NF- B
proteins and their cognate binding sites in the CD28RR of
the GM-CSF promoter are involved in recruiting chroma-
tin remodeling activities to the GM-CSF promoter as has
been shown for certain transcription factors on other genes
(44, 45). To assess this possibility, we used an in vitro
recruitment assay to determine if chromatin modifying
complexes can be recruited to the GM-CSF promoter in
a NF- B–dependent manner. An immobilized GM-CSF
template, consisting of a 75 bp region of the proximal pro-
moter from  120 to  45, encompassing the CD28RR
(17; see Fig. 1 A) was incubated with nuclear extracts from
nonstimulated and P/I-stimulated Jurkat T cells. After
washing, bound proteins were eluted in SDS load buffer,
subjected to SDS-PAGE, and analyzed by Western blot-
ting, using antibodies to specific proteins.
Little RelA is present in nuclear extracts of nonstimu-
lated Jurkat T cells, but is detected in extracts stimulated
with P/I for 30 min as expected from previous results (Fig.
5 A, lanes 1 and 2, top panel). As expected, RelA bound to
the GM-CSF template from stimulated but not nonstimu-
lated extracts (Fig. 5 A, lanes 3 and 4). Sp1 protein was de-
tected in both nonstimulated and stimulated nuclear ex-
tracts at approximately equal levels (Fig. 5 A, lanes 1 and 2,
middle panel), but significant binding of Sp1 to the GM-
CSF template was only detected from stimulated extracts
(Fig. 5 A, lane 4). In the experiments shown in Figs. 5 and
6 there are variable levels of Sp1 binding in the unstimu-
lated extracts. The reason for this variation is not clear, but
may arise because the Sp1 protein binds only weakly to the
Sp1 site in the absence of NF- B proteins and is stabilized
by binding of NF- B proteins to the adjacent sites. Re-
cruitment to the GM-CSF template of the ATPase compo-
nent of the SWI/SNF chromatin remodeling complex,
brg1, and the histone acetyl transferase CBP, representing
the two classes of chromatin altering activities was then ex-
amined. Approximately equal amounts of brg1 protein was
detected in both nonstimulated and stimulated nuclear ex-
tracts (Fig. 5 A, lanes 1 and 2, bottom panel); however, sig-
nificant binding of brg1 to the GM-CSF template was only
detected from stimulated extracts (Fig. 5 A, lane 4). In con-
trast, although CBP protein was present in nonstimulated
and both 30 min and 6 h stimulated nuclear extracts at ap-
proximately equal levels (Fig. 5 B, lanes 1–3, bottom
panel), it did not bind to the GM-CSF promoter (lanes
4–6). Therefore, brg1 but not CBP is recruited to the GM-
CSF CD28RR template in vitro after T cell activation.
To determine the timeframe of recruitment of brg1 to
the GM-CSF template, nuclear extracts that had been stim-
ulated with P/I for various times between 0–8 h were ex-
amined using the template assay. Localization of RelA to
the nucleus upon T cell stimulation is highest at 30 min af-
ter stimulation and continues at lower levels through to 8 h
(Fig. 5 C, top panel, lanes 1–6). This is reflected in binding
of RelA to the GM-CSF template (lanes 7–12). Levels of
Sp1 protein in the extracts do not change post stimulation
(Fig. 5 C, middle panel, lanes 1–6). However, Sp1 binding
Figure 4. Chromatin remodeling at the GM-
CSF promoter is dependent on NF- B proteins.
(A) EL-4 T cells were either untreated or pre-
treated for 1 h with the proteasome inhibitor
MG115, then incubated with or without P/I for
4 h. Nuclei were incubated with HaeIII restriction
enzyme and the genomic DNA analyzed by real-
time PCR analysis using primer set  I. The per-
centage change in accessibility in 4 h P/I stimulated
nuclei compared with nonstimulated nuclei was
graphed. The mean and standard error of three rep-
licate assays are shown. (B) Nuclear extracts (50  g)
from CMV-transfected (lanes 1 and 2) and mutant I B -transfected (lanes 3 and 4) EL-4 T cells, either unstimulated (lanes 1 and 3) or stimulated for 2 h
with P/I (lanes 2 and 4) were subjected to SDS-PAGE and analyzed by Western blotting with the indicated antibodies. (C) Nuclei from CMV-trans-
fected and mutant I B -transfected EL-4 T cells, either left unstimulated or stimulated for 2 h with P/I, were incubated with HaeIII restriction enzyme
and the genomic DNA analyzed by real-time PCR as in A. (D) GM-CSF mRNA levels were determined by real-time PCR analysis of cDNA prepared
from cells treated as in C, using primer set  II. The increase in GM-CSF mRNA levels upon stimulation in EL4-I B  cells was plotted relative to con-
trol (EL4-CMV) cells set at 100%. The mean and standard error of three replicate assays are shown.T
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to the GM-CSF template appeared to mimic that of RelA,
with little binding from nonstimulated extracts and binding
seen at all time points after stimulation although variable
levels of binding are seen across the time course examined
(lanes 7–12). Brg1 levels in the nucleus also remained con-
stant after T cell stimulation (Fig. 5 C, bottom panel, lanes
1–6), but maximum brg1 binding to the template was de-
tected at 30 min of stimulation (Fig. 5 C, lane 8). Lower
levels of brg1 binding were detected at all other time points
(Fig. 5 C, lanes 9–12) in parallel with RelA binding. Simi-
lar results were obtained when nuclear extracts from EL-4
T cells were used with a mouse GM-CSF template (un-
published data), which has a high degree of conservation
with the human sequence across the CD28RR (Fig. 6 A).
Thus, brg1 can bind in vitro to the GM-CSF promoter
template from stimulated but not unstimulated T cell ex-
tracts and binding appears to parallel that of RelA and Sp1.
Brg-1 Recruitment to the GM-CSF Template Is Dependent
on NF- B Proteins Binding to the CD28RR. To determine
whether brg1 recruitment to the GM-CSF promoter was
in fact dependent on NF- B and/or Sp1 binding sites and
proteins, binding studies were conducted using mutant
DNA templates. Templates were generated with mutations
in either the NF- B ( Bm) or CK-1 (CK-1m) sites, both
NF- B and CK-1 sites (CK-1/ Bm) and the Sp1 site
(Sp1m) of the CD28RR (Fig. 6 A). Binding to these tem-
plates from nonstimulated and 30 min P/I stimulated ex-
tracts was examined. Mutation of the Sp1 site, while reduc-
ing Sp1 binding, had no effect on RelA or brg1 binding
(Fig. 7 C). Mutation of the individual NF- B binding sites
( Bm and CK-1m) reduced RelA binding and in parallel
reduced brg1 binding but appeared to have no effect on
Sp1 binding (Fig. 7 B). In contrast, in the absence of both
NF- B sites (CK-1/ Bm) binding of RelA, Sp1, and brg1
were dramatically reduced (Fig. 7 D). Thus, brg1 binding
to the GM-CSF template is dependent on intact NF- B
but not Sp1 binding sites, suggesting that NF- B proteins
may recruit brg1 to the GM-CSF promoter template. In
addition, Sp1 binding is dependent on intact NF- B bind-
ing sites but not vice versa.
To further test the possibility that NF- B proteins were
involved in recruiting brg1 to the GM-CSF template, ex-
tracts were prepared from Jurkat T cells stably expressing
the mutant I B  protein. Stable expression of this mutant
considerably reduced the level of RelA in the nucleus (Fig.
7 E, compare lanes 2 and 4) and as expected binding of
RelA to the GM-CSF template was dramatically reduced
in these extracts compared with extracts from cells trans-
Figure 5. Recruitment of brg1 to the GM-CSF pro-
moter in vitro. (A) Nuclear extracts prepared from Jur-
kat T cells, either nonstimulated (lane 1) or stimulated
with P/I for 30 min (lane 2) were incubated with WT
GM-CSF template (lanes 3 and 4). Bound proteins
were resolved by SDS-PAGE and subjected to West-
ern blotting using the indicated antibodies. Lanes 1 and
2 represent 1/5th of the input extract. (B) Nonstimu-
lated (lane 1), 0.5 h (lane 2), and 6 h P/I stimulated
(lane 3) Jurkat T cell nuclear extracts were incubated
with WT GM-CSF template (lanes 4–6). Bound pro-
teins were analyzed by Western blotting with the indicated antibodies. Lanes 1 to 3 represent 1/5th of input extract. (C) Nonstimulated Jurkat T cell nu-
clear extracts (lane 1) or extracts from cells stimulated with P/I for the indicated time periods (lanes 1–6) were incubated with WT GM-CSF template
(lanes 7–12). Bound proteins were analyzed as in A.
Figure 6. Recruitment of brg1 to the GM-CSF pro-
moter is dependent on NF- B proteins. (A) Nucle-
otide sequence of the human and mouse GM-CSF
CD28RR is shown with CK-1, NF- B, and Sp1
binding sites indicated. Bases that are different in the
mouse sequence or that were mutated to generate the
mutant templates are indicated. (B) Nuclear extracts
from nonstimulated (lane 1) and 30 min P/I stimulated
(lane 2) Jurkat T cells were incubated with GM-CSF
templates as indicated (lanes 3–8). Bound proteins were
resolved by SDS-PAGE and subjected to Western
blotting using the indicated antibodies. Lanes 1 and 2
represent 1/5th of the input extract. (C and D) Nuclear
extracts from nonstimulated (lane 1) and 30 min P/I
stimulated (lane 2) Jurkat T cells were incubated with
the indicated GM-CSF templates (lanes 3–6) and ana-
lyzed as in A. (E) Nuclear extracts prepared from
CMV-transfected (CMV, lanes 1 and 2) and mutant
I B -transfected (I B , lanes 3 and 4) Jurkat T cells
were left unstimulated (lanes 1 and 3) or stimulated for
30 min with P/I (lane 2 and 4). Stimulated nuclei were
incubated with WT GM-CSF template (lanes 5 and 6)
and analyzed as in A.T
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fected with the empty CMV vector (Fig. 7 E, compare
lanes 5 and 6). This reduction in RelA binding was paral-
leled by a similar reduction in Sp1 and brg1 binding (Fig. 7
E, lane 6).
Taken together, these experiments show that in vitro
binding of brg1 to the GM-CSF promoter is dependent on
prior binding of NF- B proteins to two sites in the
CD28RR.
NF- B Bind to a Nucleosome Assembled GM-CSF Promot-
er, In Vitro. To test the possibility that NF- B proteins
are able to bind to the GM-CSF promoter in a chromatin
context before nucleosome remodeling, a 197 bp fragment
of the GM-CSF promoter ( 173 to  24) was assembled
into a nucleosome and binding of RelA examined. This
fragment contains the HinfI restriction site at  97 and cor-
responds to the region which displayed an increase in ac-
cessibility following T cell activation (see Fig. 1 C). The
GM-CSF template was radiolabeled and assembled into a
single nucleosome as assessed by a shift in the migration of
the DNA through a polyacrylamide gel (Fig. 7 A, lane 4),
compared with mock assembled DNA (lane 1). The naked
DNA was digested by the HinfI enzyme into two frag-
ments of 121 and 76 bp, as expected (Fig. 7 A, lanes 2 and
3). In contrast, the HinfI restriction site in the nucleosome
assembled DNA was protected from digestion (Fig. 7 A,
lanes 5 and 6) but the small amount of naked DNA re-
maining in the assembly reaction digested as expected.
Therefore, the GM-CSF promoter template could be as-
sembled into a single nucleosome which protected the
HinfI restriction site from digestion.
The HinfI restriction site is adjacent to the CK-1 ele-
ment in the GM-CSF promoter so binding assays were
conducted to determine whether the nucleosome could
also prevent NF- B binding (Fig. 7 B). Unstimulated and
30 min P/I stimulated Jurkat T cell extracts where incu-
bated with the DNA templates. RelA bound to the naked
DNA template from stimulated extracts as expected (Fig. 7
B, lane 4). RelA also bound to the nucleosome assembled
template from stimulated extracts, although with reduced
affinity (Fig. 7 B, lane 6). Therefore, the RelA protein is
able to access its binding sites in the GM-CSF promoter
despite the presence of a nucleosome.
Discussion
A key control point in inducible gene expression in-
volves reorganization of chromatin structure across regula-
tory regions of genes to allow access for the transcriptional
machinery. Here we have mapped chromatin accessibility
across the promoter region of the GM-CSF gene in un-
stimulated and stimulated EL-4 T cells and several impor-
tant points have emerged. First, the entire region that was
mapped from  633 to  164 showed intrinsic accessibility
to both MNase and restriction enzymes. This is in stark
contrast to a recent study on the IL-2 promoter in the same
cell type where we showed that there is no accessibility
across a large region of the IL-2 gene implying a more
“closed” chromatin configuration for this gene (30). Sec-
ond, two regions of the GM-CSF upstream sequence were
relatively inaccessible to digestion in these assays and such
regions may represent preferred nucleosome positions. The
possibility that nucleosomes are preferentially located in
these positions (centered on  100 and  400) was con-
firmed by the ability to amplify these regions and not flank-
ing regions from cross-linked mononucleosomal DNA.
While one of these proposed nucleosomes would span the
GM-CSF promoter in resting T cells, the fact that this re-
gion still displays some inherent accessibility may indicate a
fairly flexible nucleosome arrangement that allows some
access of transcription factors to their binding sites. GM-
CSF, in contrast to IL-2, has a pattern of expression that
may require flexible access to DNA binding sites in chro-
matin, being expressed in a wide variety of cell types in re-
sponse to many different signals (for a review, see reference
1). In addition, some myeloid cell types display constitutive
transcription from the GM-CSF gene with mRNA levels
being controlled at the stability level (46). Recently, the
chromatin structure across the promoters of several im-
mune function genes has been investigated. For example,
the IL-12 gene assembles a nucleosome across important
control regions including NF- B and C/EBP binding sites
(47). In contrast, the HIV and IFN  promoters contain
important transcription factor binding sites in nucleosome-
free regions (48, 49). Positioning of nucleosomes across the
promoter regions of inducible genes appears, therefore, to
be gene-specific and such differences may reflect the time-
Figure 7. NF- B can bind to the nucleosome assembled
GM-CSF promoter, in vitro. (A) A 197 bp GM-CSF pro-
moter template, either naked DNA (lanes 1–3) or nucleo-
some assembled DNA (lanes 4–6) was incubated with
varying amounts of HinfI restriction enzyme, as indicated.
The DNA was electrophoresed through 5% polyacryl-
amide gel. The positions of the nucleosomal DNA, naked
DNA, and digested DNA fragments are indicated. (B) Nu-
clear extracts prepared from Jurkat T cells, either nonstim-
ulated (lane 1) or stimulated with P/I for 30 min (lane 2)
were incubated with a naked GM-CSF template (lanes 3
and 4) or nucleosomal assembled GM-CSF template (lanes
5 and 6). Bound proteins were resolved by SDS-PAGE
and subjected to Western blotting using the indicated anti-
bodies. Lanes 1 and 2 represent 1/5th of the input extract.T
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frame or signal requirements for the response of these genes
to cell activation.
The third important finding was that the proximal pro-
moter region of the GM-CSF gene undergoes an increase
in accessibility to MNase and restriction enzymes after acti-
vation of the cells with P/I. The region that becomes re-
modeled stretches between  174 to   24 across the tran-
scription start site and encompasses the CD28RR as well as
more proximal AP-1 and NFAT/Ets binding sites. This
suggests that a single nucleosome positioned across this re-
gion may be remodeled after activation, which is similar to
the situation described for the IL-12 p40 promoter upon
activation of macrophages (47). Furthermore, the remodel-
ing events at both the GM-CSF and IL-12 promoters oc-
cur 1 h after stimulation (47). In addition, chromatin
changes in both genes are dependent upon a primary stim-
ulus (P/I for GM-CSF and LPS for IL-12) but not en-
hanced by a secondary stimulus (CD28 for GM-CSF and
IFN-  for IL-12) (47). Importantly, an increase in GM-
CSF mRNA levels is detected at 2 h and nuclear run-on
assays have shown that transcription is induced in 2 h (50),
only after the chromatin remodeling events have occurred.
Therefore, chromatin remodeling events at the GM-CSF
promoter may be a critical initiating step in activation of
GM-CSF gene transcription.
Several pieces of evidence have previously shown the
importance of the CD28RR in GM-CSF promoter func-
tion particularly in a chromatin context. First, a mutation
in the CD28RR, that altered the specific NF- B family
members that bound to the GM-CSF  B site, eliminated
promoter activity in transgenic mice and in stable cell lines
but not in transient transfections (21). This mutation also
specifically prevented the formation of a DNase I hyper-
sensitive site in the promoter that was normally detected in
the wild-type transgene (21) and in the native human gene
(20). Second, a triplex-forming oligonucleotide directed
against the NF- B/Sp1 region efficiently inhibited consti-
tutive GM-CSF expression in Juvenile Myelomonocytic
Leukemic cells (9) as well as inducible expression in Jurkat
T cells (51), suggesting an important role for this region in
transcription from the endogenous gene.
These results presented here suggest that specific NF- B
family proteins bound to the GM-CSF promoter are im-
portant for recruiting chromatin remodeling activities
which bring about changes in chromatin structure. The
SWI/SNF chromatin remodeling complex is a likely candi-
date for such an activity, given that we have now shown
that brg1 can be recruited to the GM-CSF promoter in
vitro in an NF- B–dependent manner. From these in vitro
binding experiments, a model can be proposed whereby
NF- B proteins first interact with the CD28RR. This in
turn leads to both Sp1 binding and brg1 recruitment to the
promoter although brg1 recruitment does not appear to
depend on Sp1 binding. While Sp1 was not required for
recruitment of brg1 in vitro it may play a role in stabilizing
the complex in a chromatin context or in the recruitment
of coactivators or the transcription machinery after chro-
matin remodeling and further studies are required to deter-
mine this role. Similarly, while the histone acetyl trans-
ferase CBP was not recruited to the CD28RR region of
the GM-CSF promoter, in vitro, this does not rule out the
involvement of CBP or other histone acetylases in GM-
CSF promoter activation.
It has previously been shown that a brg1-containing
complex binds more tightly to chromatin after Jurkat T cell
activation (52) in keeping with the possibility that brg1 is
recruited to the GM-CSF promoter in vivo. SWI/SNF
complexes have been shown to be recruited to other pro-
moters through interaction with specific transcription fac-
tors (44, 45) but this is the first example of brg1 complexes
being dependent on NF- B for binding at least in vitro.
This model would suggest that NF- B proteins may be
able to access their binding sites in the CD28RR in a chro-
matin context. In support of this is the finding that a nu-
cleosome can be assembled across the GM-CSF promoter
region in vitro and that RelA can still bind, although with
reduced affinity, to the nucleosome-assembled GM-CSF
promoter. This is in contrast to a recent study on the IL-2
gene, where binding of NF- B proteins was completely
inhibited by the assembly of a nucleosome over the pro-
moter (53).
Aberrant expression of NF- B is often a feature of
pathological conditions such as leukemia, other cancers,
and chronic inflammatory diseases. For example, the con-
stitutive activation of NF- B proteins has been reported as
a distinguishing characteristic of leukemic stem cells (54). It
is possible then that in such conditions a key checkpoint in
the control of GM-CSF expression may be circumvented
so that the chromatin structure of the GM-CSF promoter
is in a constitutively ‘open’ state. This may contribute to
the inappropriate expression of GM-CSF often observed in
these conditions. Thus, defining the mechanism by which
chromatin remodeling complexes are recruited to genes
such as GM-CSF may provide novel therapeutic targets for
these diseases.
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